GSK plc (LON:GSK) Insider Buys £9,147.46 in Stock

GSK plc (LON:GSK) insider Elizabeth (Liz) McKee Anderson acquired 446 shares of the business’s stock in a transaction on Monday, September 23rd. The stock was acquired at an average price of GBX 2,051 ($27.46) per share, with a total value of £9,147.46 ($12,248.88).

GSK Stock Down 0.2 %

GSK stock opened at GBX 1,527 ($20.45) on Thursday. The stock has a market capitalization of £62.30 billion, a PE ratio of 1,351.33, a price-to-earnings-growth ratio of 1.34 and a beta of 0.31. The company has a fifty day moving average of GBX 1,583.71 and a 200-day moving average of GBX 1,629.81. The company has a debt-to-equity ratio of 123.04, a quick ratio of 0.73 and a current ratio of 0.82. GSK plc has a one year low of GBX 1,371.40 ($18.36) and a one year high of GBX 1,823.50 ($24.42).

GSK Dividend Announcement

The firm also recently announced a dividend, which will be paid on Thursday, October 10th. Stockholders of record on Thursday, August 15th will be paid a dividend of GBX 15 ($0.20) per share. This represents a dividend yield of 0.97%. The ex-dividend date is Thursday, August 15th. GSK’s dividend payout ratio (DPR) is 5,309.73%.

Analysts Set New Price Targets

A number of analysts have issued reports on GSK shares. Shore Capital reiterated a “buy” rating on shares of GSK in a research note on Wednesday, August 28th. Deutsche Bank Aktiengesellschaft reissued a “buy” rating and issued a GBX 1,850 ($24.77) price target on shares of GSK in a research report on Tuesday, September 3rd. Jefferies Financial Group reaffirmed a “buy” rating and set a GBX 2,100 ($28.12) price objective on shares of GSK in a research report on Thursday, June 27th. Citigroup lowered their target price on GSK from GBX 2,120 ($28.39) to GBX 1,900 ($25.44) and set a “buy” rating for the company in a research note on Friday, July 5th. Finally, Berenberg Bank reiterated a “buy” rating and issued a GBX 1,820 ($24.37) price objective on shares of GSK in a research note on Tuesday, September 10th. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and five have given a buy rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of GBX 1,842.50 ($24.67).

GSK Company Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.